ConforMIS Names Dan Krupp Senior Vice President U.S. Sales
July 11 2017 - 4:10PM
ConforMIS, Inc. (NASDAQ:CFMS), a medical technology company that
offers joint replacement implants customized to fit each patient’s
unique anatomy, today announced that Dan Krupp has joined the
Company as its Senior Vice President of U.S. Sales, effective July
3, 2017.
A photo accompanying this announcement is available
at http://www.globenewswire.com/NewsRoom/AttachmentNg/75f70387-ab76-48cd-bf98-27c3569e87df.
“The addition of Dan to our leadership team is another example
of our commitment to developing additional expertise and support
that will help us execute our commercial strategy,” said Mark
Augusti, Chief Executive Officer and President of ConforMIS. “We
are very excited to have Dan join us. His extensive experience in
leading top-ranked sales organizations in startup, turnaround,
volatile, and growth markets will be a tremendous asset for
ConforMIS.”
Mr. Krupp has more than 20 years of sales and marketing
experience in medical devices and total joint arthroplasty. From
2002-2014, he held positions of increasing responsibility at DePuy
Synthes, developing and executing sales strategies and managing
multiple new product launches. Most recently, he was Vice
President, Sales and Marketing, at JACE Medical, where he
successfully managed the development and execution of a range of
corporate and product branding initiatives.
“I am very pleased to be joining the outstanding team at
ConforMIS and to play a role in reshaping the future of
arthroplasty with the company’s disruptive technology platform,”
said Mr. Krupp. “I look forward to leading the U.S. sales force
during what we believe will be a transformative period in
orthopedics.”
About ConforMIS, Inc.
ConforMIS is a medical technology company that uses its
proprietary iFit Image-to-Implant technology platform to develop,
manufacture and sell joint replacement implants that are
individually sized and shaped, or customized, to fit each patient’s
unique anatomy. ConforMIS offers a broad line of customized knee
implants and pre-sterilized, single-use instruments delivered in a
single package to the hospital. In clinical studies, ConforMIS
iTotal CR demonstrated superior clinical outcomes, including better
function and greater patient satisfaction, compared to traditional,
off-the-shelf implants. ConforMIS owns or exclusively in-licenses
approximately 450 issued patents and pending patent applications
that cover customized implants and patient-specific instrumentation
for all major joints.
For more information, visit www.conformis.com. To receive future
releases in e-mail alerts, sign up at http://ir.conformis.com/.
Cautionary Statement Regarding Forward-Looking
Statements
Any statements in this press release about future expectations,
plans and prospects for ConforMIS, including statements about
ConforMIS’s commercial strategy, future results, and orthopedic and
arthroplasty markets, as well as other statements containing the
words “anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,”
“project,” “should,” “target,” “will,” or “would” and similar
expressions, constitute forward-looking statements within the
meaning of the safe harbor provisions of The Private Securities
Litigation Reform Act of 1995. We may not actually achieve the
plans, intentions or expectations disclosed in our forward-looking
statements, and you should not place undue reliance on our
forward-looking statements. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
the forward-looking statements we make as a result of a variety of
risks and uncertainties, including risks related to our clinical
studies and the other risks and uncertainties described in the
“Risk Factors” sections of our public filings with the Securities
and Exchange Commission. In addition, the forward-looking
statements included in this press release represent ConforMIS’s
views as of the date hereof. ConforMIS anticipates that subsequent
events and developments may cause ConforMIS’s views to change.
However, while ConforMIS may elect to update these forward-looking
statements at some point in the future, ConforMIS specifically
disclaims any obligation to do so. These forward-looking statements
should not be relied upon as representing ConforMIS’s views as of
any date subsequent to the date hereof.
The photo is also available via AP PhotoExpress.
Investor Contact:
Oksana Bradley
ir@conformis.com
(781) 374-5598
Media Contact:
Bill Berry
Berry & Company Public Relations
Bberry@berrypr.com
(212) 253-8881
Conformis (NASDAQ:CFMS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Conformis (NASDAQ:CFMS)
Historical Stock Chart
From Apr 2023 to Apr 2024